P‐46 A placebo‐controlled, double‐blinded study of recombinant IFNγ in dogs with atopic dermatitis

Abstract

A placebo‐controlled, double‐blinded clinical study of canine recombinant IFNγ (KT‐100) was conducted in dogs with atopic dermatitis at 31 animal hospitals in Japan that met the Good Clinical Practices standard. Based on the results of a preceding dose‐finding study, KT‐100 was administered subcutaneously at a dose of 10 000 units/kg body weight three times a week for 2 weeks. Efficacy analysis was performed using data obtained from 100 dogs (50 in the KT‐100 group and 50 in the placebo group). The veterinarian's evaluation, the dog owner's evaluation, and the clinical skin score (total score for erythema, pigmentation and alopecia) showed marked improvement with a significant reduction in the area of the lesions in the KT‐100 group compared with the placebo group. Animals in both groups were subjected to an additional 2‐week treatment with KT‐100 using the same dosage; the therapeutic effects lasted at least 2 weeks after the termination of treatment. For safety evaluation, 134 dogs (65 in the KT‐100 group and 69 in the placebo group) were observed for 2 weeks after additional treatment with KT‐100 for a total of 42 days, but none of them presented with any adverse events except one dog with soft stools. These results suggest that KT‐100 is efficacious and safe for the treatment of atopic dermatitis in dogs. Funding: Toray Industries, Inc.